HHS to Dedicate $4.8 Billion to COVID-19 Testing for the Uninsured
WASHINGTON – Tuesday, the US Department of Health and Human Services, through the Health Resources and Services Administration, announced that it is dedicating $4.8 billion from the American Rescue Plan to support the HRSA COVID-19 Uninsured Program. This funding will allow the program to continue reimbursing health care providers for testing uninsured individuals for COVID-19. As of May 19, 2021, the program has issued nearly $4 billion in testing reimbursements to providers.
“As we vaccinate the country, let’s continue taking the preventive measures necessary to keep the virus under control and prevent it from spreading. Testing remains critical and now it’s available at no cost to those who need it,” said HHS Secretary Xavier Becerra. “This funding will help ensure everyone has access to testing regardless of whether they have health insurance.”
There are approximately 29 million uninsured individuals living in the United States. While this administration has been focused on decreasing the uninsured rate, as evidenced by the more than 1 million people who have enrolled into quality health coverage through the Special Enrollment Period much work remains. By ensuring programs like the HRSA COVID-19 Uninsured Program remains adequately funded, this administration is removing cost impediments so anyone exposed to COVID-19 may seek appropriate testing and care.
The funding announced today is dedicated to COVID-19 testing. HRSA also helps uninsured individuals’ access COVID-19 treatment and vaccinations through the COVID-19 Uninsured Program. The program reimburses providers at national Medicare rates for providing these services. As of May 19, 2021, the program has issued over $2.5 billion toward reimbursing providers for delivering COVID-19 treatment and over $85 million for vaccinating the uninsured.
“Focusing on the underserved and eliminating health access barriers for vulnerable communities is a core part of our mission,” said Acting HRSA Administrator Diana Espinosa. “To truly return to normal after the pandemic, we must continue to test, treat and vaccinate everyone, regardless of insurance or immigration status.”
Learn more about the HRSA COVID-19 Uninsured Program here.
In The News
Health
Voting
Health
Vaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world yet another weapon against the virus at a time when developing countries are desperate... Read More
CAPE TOWN, South Africa (AP) — U.S. plans to donate 500 million more COVID-19 vaccines to developing countries were met Thursday with both celebration and hesitation amid questions over whether the effort will be enough to help poor regions desperate for doses. Some health officials and... Read More
The FDA has authorized the first aid for diagnosing Autism Spectrum Disorder in children 18 months through 5 years of age called Canvas Dx. It was developed by Cognoa, a behavioral health company. “Currently, pediatricians refer most children with suspected developmental delay to specialists to diagnose... Read More
Why do some people get side effects after COVID-19 vaccines? Temporary side effects including headache, fatigue and fever are signs the immune system is revving up -- a normal response to vaccines. And they're common. "The day after getting these vaccines, I wouldn't plan anything that... Read More
Rep. Tom O’Halleran, D-Ariz., has joined Rep. Jodey Arrington, R- Texas, and a bipartisan group of members in a drive to improve the performance standards for health care providers who participate in Medicare’s Accountable Care Organizations, which are part of the Medicare Shared Savings Program. “For... Read More
The Supreme Court this week decided to leave in place a $2 billion verdict in favor of women who claim they developed ovarian cancer from using Johnson & Johnson talc products. As is their custom, the justices did not comment Tuesday on why they rejected Johnson & Johnson's... Read More
